Latest News and Press Releases
Want to stay updated on the latest news?
-
AMES, Iowa, April 21, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer,...
-
AMES, Iowa, April 13, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), today announced that it will release its first quarter 2017 financial results on Thursday, May 4, 2017....
-
AMES, Iowa, April 04, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer,...
-
AMES, Iowa, March 01, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with...
-
AMES, Iowa, Feb. 28, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer,...
-
AMES, Iowa, Feb. 20, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), today reported that it will release its fourth quarter and year end 2016 financial results on Tuesday,...
-
AMES, Iowa, Feb. 13, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer,...
-
AMES, Iowa, Nov. 09, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer,...
-
AMES, Iowa, Nov. 01, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with...
-
Two Distinct IDO Pathway Inhibitors in Clinical Development Indoximod, Exclusive to NewLink GeneticsGDC-0919 in Partnership with Genentech, a Member of the Roche Group AMES, Iowa & NEW YORK,...